Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: An ongoing cross-sectional study

BMJ Open

Volumn 6, Issue 2, 2016, Pages

  Mesher, David ^a   Panwar, Kavita ^a   Thomas, Sara L ^b   Beddows, Simon ^a   Soldan, Kate ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHLAMYDIA; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREVALENCE; SEXUALITY; UNITED KINGDOM; VACCINATION; YOUNG ADULT; ENGLAND; HEALTH SURVEY; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADOLESCENT; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; PREVALENCE; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84960331133     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009915     Document Type: Article

References (27)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
2. IARC Working Group. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France: World Health Organisation International Agency for Research on Cancer, 2012.
3. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927-35.
4. Mesher D, Cuschieri K, Hibbitts S, et al. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation. J Clin Pathol 2015;68:135-40.
5. Bosch FX, Broker TR, Forman D, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013;31(Suppl 8):I1-31.
6. Cervical Cancer Action. Global Progress in HPV Vaccination. http://www.cervicalcanceraction.org/comments/comments3.php (accessed Nov. 2014).
7. Department of Health, Health Protection Agency. Annual HPV vaccine uptake in England: 2010/11. http://webarchive. nationalarchives.gov. uk/20130107105354/https://www.wp. dh.gov. uk/immunisation/files/2012/03/120319-HPV-UptakeReport2010-11-revised-acc.pdf (accessed Apr. 2015).
8. Department of Health, Health Protection Agency. Annual HPV vaccine uptake in England: 2011/12. http://webarchive. nationalarchives.gov. uk/20130123170526/http://immunisation. dh.gov. uk/ann-hpv-vac-cover-england-201112/(accessed Apr. 2015).
9. Public Health England. Annual HPV vaccine coverage in England: 2012/13. https://www.gov. uk/government/uploads/system/uploads/attachment-data/file/266190/HPV-AnnualDataTable2012-13-SHA-acc2.pdf (accessed Apr. 2015).
10. Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012;30(Suppl 5):F139-48.
11. Public Health England. Human Papillomavirus (HPV) Vaccine Coverage in England, 2008/09 to 2013/14: A review of the full six years of the three-dose schedule. https://www gov uk/government/uploads/system/uploads/attachment-data/file/412264/HPV-Vaccine-Coverage-in-England-200809-to-201314 pdf 2015 (accessed Oct. 2015).
12. Rondy M, Van Lier A, Van De Kassteele J, et al. Determinants for HPV vaccine uptake in the Netherlands: a multilevel study. Vaccine 2010;28:2070-5.
13. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013;32:26-32.
14. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012;206:1645-51.
15. Cummings T, Zimet GD, Brown D, et al. Reduction of HPV infections through vaccination among at-risk urban adolescents. Vaccine 2012;30:5496-9.
16. Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012;130:e249-56.
17. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013;208:385-93.
18. Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014;110:2804-11.
19. Soderlund-Strand A, Uhnoo I, Dillner J. Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study. Cancer Epidemiol Biomarkers Prev 2014;23:2757-64.
20. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-35.
21. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:781-9.
22. Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100-10.
23. Howell-Jones R, De Silva N, Akpan M, et al. Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation. Vaccine 2012;30:3867-75.
24. Bissett SL, Howell-Jones R, Swift C, et al. Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol 2011;83:1744-51.
25. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711-23.
26. Department of Health, Health Protection Agency. Annual HPV vaccine coverage in England in 2009/2010. https://www.gov. uk/government/publications/annual-hpv-vaccine-coverage-in-england-in-2009-2010 (access Apr. 2015).
27. Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015;15:565-80.